Welcome to NHTherapeutics
NHTherapeutics (NHT) stands for Neurohormone Therapeutics and is a clinical stage stage pharmaceutical company that aims to normalize hormonal levels in patients suffering from decreased hormonal levels (hypogonadism) due to aging or disease. Unlike existing therapy, NHT treats hypogonadism endogenously at the level of the brain.
The company’s lead compound, NH901, represents a previously approved drug that is being repurposed as a non-scheduled drug for hypogonadism. The compound is safe, well-tolerated and historical clinical data for both the indication and the formulation exist, making this a low risk project. The company has a strong management team and a clear development strategy that maximizes clinical success.
NHT’s development milestones and exit strategy enable early strategic partnerships and a potential early exit for investors as well as long term gain.